Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 5 of 33« First...34567...102030...Last »

Special Feature: First Year After Launch

The new generation of hep C drugs has completely changed the conversation about launches.

Read More »

U.S. court backs UCB drug patent, shares jump

A ruling by the Delaware District Court in the United States upheld the validity of UCB’s patent for the epilepsy drug Vimpat.

Read More »

UK cost approval for longer use of heart drug

Long term use of AstraZeneca’s blood thinner Brilinta has been recommended as a cost-effective option in the UK for treating patients after a heart attack.

Read More »

Bristol-Myers shares hit by decline of Yervoy

Bristol-Myers Squibb reported disappointing 2Q 2016 sales of its Yervoy melanoma treatment.

Read More »

J&J shares on track for record high

J&J raised its full-year 2016 sales and earnings forecasts and reported quarterly results that beat estimates, helped by strength in its Rx drugs business.

Read More »

U.S. health spending to rise 5.8% a year through 2025

Healthcare spending in the United States will likely grow by an average 5.8 percent per year over the next decade according to updated projections from the federal government.

Read More »

Future of Post-Patent Protection for Humira

Investors in AbbVie are getting a bit antsy as that company’s blockbuster rheumatoid arthritis drug Humira loses its patent protection later this year.

Read More »

WHO backs cut in yellow fever vaccine dose

World Health Organization advisers have recommended using a fifth of the standard dose of yellow fever vaccine in the event of a global shortage to combat the worst outbreak of the deadly disease in decades.

Read More »

Senators introduce bill supporting generic drugs

Four U.S. senators introduced a bill aimed at preventing big pharmaceutical companies from using safety rules to prevent generic drugs from coming to market.

Read More »

2016 Annual Report: State Of The Bio Industry

The outlook remains bright due to a favorable regulatory arena, support for biopharma-friendly legislation and development incentives, expanding scientific opportunities in key therapeutic areas such as immuno-oncology, and big pharma’s continued push to obtain innovation.

Read More »

Rise of the biosimilars in the United States

IMS analysis revealed that lower-cost copies of complex biotechnology drugs could save the United States and Europe’s five top markets as much as €98 billion ($110 billion) by 2020.

Read More »

Cancer drug prices highest in U.S., least affordable in India, China: study

Americans pay the highest prices in the world for cancer drugs, but the treatments are least affordable in lower income countries.

Read More »

Botswana gets GSK’s modern HIV drug in largest ever Africa tender

An HIV drug approved less than 3 years ago is to be rolled out in Botswana as a core medicine for newly diagnosed patients.

Read More »

Drugmakers eye volume growth as China cuts prices by up to 67 percent

Chinese health authorities announced price cuts of up to two-thirds for three expensive drugs.

Read More »

Roche breast cancer drug Perjeta rejected by UK cost agency

Roche’s breast cancer drug Perjeta (pertuzumab) has been turned down for use on Britain’s state health service.

Read More »

India Patent Office approves Gilead’s hepatitis C drug patent

India has reversed course and granted approval to Gilead Sciences’ patent for its hepatitis C drug Sovaldi.

Read More »

Regeneron secures more coverage for cholesterol drug Praluent

Regeneron Pharmaceuticals, facing slowing sales of blockbuster eye drug Eylea, said it was making substantial progress in securing more insurance coverage for cholesterol drug Praluent.

Read More »

France gets G7 to discuss global regulation of medicine prices

France will press its G7 partners this month to launch an “irreversible” process to control the prices of new medicines, part of a global drive to make life-saving drugs more affordable.

Read More »

UK agency backs cancer drug after Sanofi cuts price

Britain’s healthcare cost watchdog NICE said on Friday it had changed its mind and decided to recommend Sanofi’s prostate cancer drug Jevtana after the French company agreed to a further discount.   The National Institute for Health and Care Excellence (NICE) said the improved discount was “an excellent example of how pharma companies can work […]

Read More »

New heart drugs struggle to win sales as doctors hold back

New heart drugs hailed as breakthrough treatments by researchers are struggling to gain traction among prescribing doctors, posing a headache for makers such as Novartis, which reported more weak sales for its Entresto medicine.

Read More »

Page 5 of 33« First...34567...102030...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

December 2017 Focus: Ad Agency Roundtable and more!


Ad Right Bottom

Main Navigation